share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  09/13 20:56

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. has announced a series of significant corporate developments in recent filings with the SEC. On September 9, 2024, the company amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the potential sale of Placement Shares to $50 million. Additionally, on September 12, 2024, Allarity Therapeutics reported the resignation of Joan Y. Brown as Chief Financial Officer, effective immediately. Her departure was not due to any disagreements with the company's practices or policies. On the same day, the company's Board of Directors appointed Alexander Epshinsky as the new CFO. Epshinsky, a seasoned finance professional with experience in the pharmaceutical and biotech sectors, has entered into an Employment Agreement with Allarity Therapeutics, which includes a $340,000 annual base salary, potential performance-based increases, equity in the form of restricted stock units, and eligibility for annual bonuses, among other benefits. The company has also indicated a renewed focus on financing strategies to support its operational and strategic goals following the recent changes in management.
Allarity Therapeutics, Inc. has announced a series of significant corporate developments in recent filings with the SEC. On September 9, 2024, the company amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the potential sale of Placement Shares to $50 million. Additionally, on September 12, 2024, Allarity Therapeutics reported the resignation of Joan Y. Brown as Chief Financial Officer, effective immediately. Her departure was not due to any disagreements with the company's practices or policies. On the same day, the company's Board of Directors appointed Alexander Epshinsky as the new CFO. Epshinsky, a seasoned finance professional with experience in the pharmaceutical and biotech sectors, has entered into an Employment Agreement with Allarity Therapeutics, which includes a $340,000 annual base salary, potential performance-based increases, equity in the form of restricted stock units, and eligibility for annual bonuses, among other benefits. The company has also indicated a renewed focus on financing strategies to support its operational and strategic goals following the recent changes in management.
Allarity Therapeutics, Inc.在最近提交給美國證券交易委員會（SEC）的文件中宣佈了一系列重大企業發展消息。2024年9月9日，該公司與Ascendiant Capital Markets, LLC修訂了市場發行銷售協議，將募集股票的潛在銷售額提高至5000萬美元。此外，Allarity Therapeutics於2024年9月12日報告稱，財務總監Joan Y. Brown立即辭職。她的離職並非因與公司的做法或政策存在任何分歧。同一天，公司董事會任命Alexander Epshinsky擔任新的財務總監。Epshinsky是一位經驗豐富的金融專業人士，擁有藥品和生物技術行業的經驗，與Allarity Therapeutics簽訂了僱傭合同，該合同包括年薪34萬美元、潛在基於業績的增加、以受限制股票單位形式的股權以及有資格獲得年度獎金等多項福利。該公司還表示，在最近管理層變動後，將重新關注支持其運營和戰略目標的融資策略。
Allarity Therapeutics, Inc.在最近提交給美國證券交易委員會（SEC）的文件中宣佈了一系列重大企業發展消息。2024年9月9日，該公司與Ascendiant Capital Markets, LLC修訂了市場發行銷售協議，將募集股票的潛在銷售額提高至5000萬美元。此外，Allarity Therapeutics於2024年9月12日報告稱，財務總監Joan Y. Brown立即辭職。她的離職並非因與公司的做法或政策存在任何分歧。同一天，公司董事會任命Alexander Epshinsky擔任新的財務總監。Epshinsky是一位經驗豐富的金融專業人士，擁有藥品和生物技術行業的經驗，與Allarity Therapeutics簽訂了僱傭合同，該合同包括年薪34萬美元、潛在基於業績的增加、以受限制股票單位形式的股權以及有資格獲得年度獎金等多項福利。該公司還表示，在最近管理層變動後，將重新關注支持其運營和戰略目標的融資策略。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間